Leidos shares declined by approximately 1.4% in the most recent session, underperforming the broader market’s 0.8% gain. Trading volume rose 25% above the 30-day average, indicating elevated investor attention. Institutional investors increased their holdings by 1.2 million shares in the latest 13F filings, suggesting a mix of profit-taking and portfolio rebalancing ahead of the company’s Q3 earnings announcement.

Leidos has outperformed consensus EPS estimates in seven of the last eight quarters, delivering an average surprise of +6.5%. Analysts currently project Q3 revenue of $3.35 billion and adjusted EPS of $2.10, representing year-over-year growth of 8% and 12% respectively. The company’s track record of conservative guidance and execution has fueled expectations for another upside surprise when results are reported next month.

The firm’s total backlog increased 10% year-over-year to $27.4 billion, driven by recent awards in defense, healthcare IT, and environmental services. Notable wins include a five-year, $1.2 billion cybersecurity contract with a federal civilian agency and a $350 million IT modernization task order for a major public health department. These awards bolster visibility into revenue through 2026 and underscore Leidos’s strength in high-margin, mission-critical services.

Management reaffirmed full-year 2026 revenue guidance in the range of $13.0–$13.2 billion and adjusted operating margin of 10.5–11.0%. Eight of ten analysts covering the stock maintain a Buy rating, with a consensus price target implying 15% upside. Recent upgrades highlight improved margin trends in the solutions division and accelerating growth in commercial contracts, supporting a positive outlook for the next two quarters.